Figure 2.

Improvement in reported GI symptoms (mean ± SD). Blue columns represent the BG-1-4^TM group. Red columns represent the placebo group. Primary outcomes: total GSRS, constipation, and diarrhoea. Constipation improved for the experimental BG01-4^TM group but not the control, with the alpha level (0.05) adjusted for multiple comparisons (* p = 0.0167 = 0.05/3). Diarrhoea was significantly improved for both the experimental and placebo groups. The total GSRS score improved by 11% compared to the placebo (⁺ p < 0.05 improvement over 4 weeks). Pre-planned secondary outcomes: All experimental and placebo groups were improved. Indigestion improved in the BG01-4^TM group by 32% compared to the placebo group (21%; p = 0.079). Constipation and indigestion are both primarily controlled by lower GI tract function.